Evogene Ltd.(EVGN)Earnings, Financials & Key RatiosEvogene Ltd. (EVGN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's fundamental outlook is constrained by a persistent free cash flow deficit and an equity position that has deteriorated into negative territory at -$2.5 million.
Evogene Ltd. (EVGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Evogene Ltd. (EVGN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.60vs $0.27-122.2% | $334,000vs $350,000-4.6% |
| Q2 2026 | Mar 5, 2026 | $0.61vs $0.26-134.6% | $314,000vs $275,000+14.2% |
| Q4 2025 | Nov 20, 2025 | $0.31vs $0.26-19.2% | $312,000vs $275,000+13.5% |
| Q3 2025 | Aug 28, 2025 | $1.06 | $884,000 |
Recent stock market news and headlines for Evogene Ltd. (EVGN)
Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines, improving scalability, and increasing the likelihood of success. REHOVOT, Israel, June 24, 2026 /PRNewswire/ -- Evogene Ltd.
Key metrics vs top competitors for Evogene Ltd. (EVGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.42 | $3.66M | -0.39 | -30.91% | -220.22% | -63.29% | — | |
| $5.51 | $1.66B | -3.91 | 146.73% | -646.99% | -1768.51% | — | |
| $28.31 | $1.46B | -70.78 | 13.79% | -1.98% | -2.61% | — | |
| $281.27 | $40.28B | -185.05 | 35.9% | -9.05% | -15.13% | — | |
| $86.75 | $58.24B | 54.22 | 2.92% | 6.5% | 4.62% | — | |
| $11.59 | $1.45B | -0.65 | -18.34% | -72.93% | -82.27% | — |
Evogene Ltd. (EVGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EVGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Evogene Ltd. (EVGN) stock FAQ — growth, dividends, profitability & financials explained
Evogene Ltd. (EVGN) reported $5.4M in revenue for fiscal year 2025. This represents a 69% decrease from $17.1M in 2012.
Evogene Ltd. (EVGN) saw revenue decline by 30.9% over the past year.
Evogene Ltd. (EVGN) reported a net loss of $13.7M for fiscal year 2025.
Evogene Ltd. (EVGN) has a return on equity (ROE) of -63.3%. Negative ROE indicates the company is unprofitable.
Evogene Ltd. (EVGN) had negative free cash flow of $12.1M in fiscal year 2025, likely due to heavy capital investments.
